Displaying items by tag: vaccine
Wednesday, 14 December 2022 01:48
Moderna receives FDA clearance for emergency use of Covid-19 booster vaccine
Moderna, Inc., a biotechnology company pioneering messenger ARN (ARNm), therapeutics and vaccines, received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for its bivalent Covid-19 mRNA-1273.222 booster vaccine intended to protect against BA.4/BA.5 variant omicron in children aged 6 months to 5 years.
Published in
Experts
Monday, 17 October 2022 03:27
Moderna receives FDA clearance for emergency use of booster vaccine
Moderna, Inc, a biotechnology company pioneering messenger ARN (ARNm), therapeutics and vaccines, announced today that it received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its bivalent COVID-19 booster vaccine targeting omicron BA.4/BA, 5, mRNA-1273.222, for children and adolescents 6 to 17 years of age.
Published in
Experts